Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay-Reference-Cited by-同舟云学术

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay

Published:2022-05-11 Issue:5 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Arbo Antonio¹^ORCID,Martinez-Cuellar Celia¹,Vazquez Cynthia²,Bellier Lucile³,Adorno Cecilia⁴,Dibarboure Hugo⁵,Lopez Juan Guillermo⁶,Petitjean Audrey⁷,Bianculli Pablo⁸^ORCID

Affiliation:

1. Institute of Tropical Medicine, Faculty of Medicine, National University of Paraguay, Asunción, Paraguay

2. Virology Department, Laboratorio Central de Salud Pública, Asunción, Paraguay

3. Health Economics and Outcomes Research, Creativ-Ceutical, London, UK

4. Vaccines Unit, Sanofi Pasteur, Asunción, Paraguay

5. Public Affairs, Sanofi Pasteur South Cone, Montevideo, Uruguay

6. Market Access, Sanofi, Mexico City, Mexico

7. Health Economics and Outcomes Research, Sanofi Pasteur, Lyon, France

8. Value & Access, Sanofi Pasteur South Cone, Buenos Aires, Argentina

Funder

SANOFI Pasteur

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2069974

Reference43 articles.

1. Epidemiology and pathogenesis of influenza

2. Arbeitskreis blut, untergruppe «Bewertung Blutassoziierter Krankheitserreger» “Influenza Virus” Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2009;36(1):32–39.

3. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project

4. WHO SAGE seasonal influenza vaccination recommendations during the COVID-19 pandemic; 2020.